Compugen Ltd (CGEN) Stock Price

CGENStock

$1.96+0.51%52W

Market Cap$185.66M

P/E5.25x

PEG Ratio1.29

Div yield—

Beta2.79

CGEN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-41.85%

Price vs S&P 500 (4W)-18.18%

PEG Ratio1.29

VGM Score69.88

P/E Ratio (Annual)5.25x

P/CF (Annual)5.87x

Book Value / Share (Quarterly)$0.94

P/TBV (Annual)0.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)113.28%

Cash Flow / Share (Quarterly)$0.30

Price vs S&P 500 (YTD)16.18%

Gross Margin (TTM)87.00%

Net Profit Margin (TTM)-420.79%

EPS (TTM)$0.36

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$0.36

Revenue Growth (5Y)105.20%

EPS (Annual)$0.38

ROI (Annual)34.40%

Gross Margin (Annual)94.01%

Net Profit Margin (5Y Avg)-443.04%

Cash / Share (Quarterly)$1.32

P/E Basic Excl Extra (TTM)5.28x

Revenue Growth QoQ (YoY)4480.41%

P/E Normalized (Annual)5.25x

ROA (Last FY)22.57%

Revenue Growth TTM (YoY)161.14%

EBITD / Share (TTM)$0.50

ROE (5Y Avg)-41.50%

Operating Margin (TTM)-460.07%

Cash Flow / Share (Annual)$0.33

P/B Ratio2.09x

P/B Ratio (Quarterly)2.28x

Net Income / Employee (Annual)$666,800

EV / Revenue (TTM)2.87x

Net Interest Coverage (TTM)0.50x

ROA (TTM)26.13%

EV / EBITDA (TTM)3.69x

EPS Incl Extra (Annual)$0.38

Current Ratio (Annual)6.56x

Quick Ratio (Quarterly)5.72x

3-Month Avg Trading Volume0.25M

52-Week Price Return0.51%

EV / Free Cash Flow (Annual)5.60x

P/E Incl Extra (TTM)5.28x

Revenue / Employee (TTM)$108,695,600,000

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)5.55x

Asset Turnover (Annual)0.28x

52-Week High$3.23

Operating Margin (5Y Avg)-462.61%

EPS Excl Extra (Annual)$0.38

CapEx CAGR (5Y)4.81%

Tangible BV CAGR (5Y)21.53%

26-Week Price Return-31.94%

Quick Ratio (Annual)6.47x

13-Week Price Return-17.30%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.72x

Enterprise Value$175.39M

Revenue / Share Growth (5Y)98.61%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)9.44%

Revenue / Employee (Annual)$631,300

Inventory Turnover (Annual)28.20x

Pretax Margin (Annual)-29.24%

Cash / Share (Annual)$1.54

3-Month Return Std Dev51.60%

Gross Margin (5Y Avg)91.74%

Net Income / Employee (TTM)$664,000

ROE (Last FY)34.40%

Net Interest Coverage (Annual)11.00x

EPS Basic Excl Extra (Annual)$0.38

P/FCF (TTM)5.28x

Receivables Turnover (TTM)2.68x

EV / Free Cash Flow (TTM)6.23x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.36

Receivables Turnover (Annual)29.70x

ROI (TTM)42.57%

P/S Ratio (TTM)7.53x

Pretax Margin (5Y Avg)-445.03%

Revenue / Share (Annual)$0.38

Tangible BV / Share (Annual)$0.90

Price vs S&P 500 (52W)-15.02%

P/E Ratio (TTM)5.28x

EPS Growth TTM (YoY)20.54%

Year-to-Date Return28.10%

5-Day Price Return-5.31%

EPS Normalized (Annual)$0.38

ROA (5Y Avg)-33.24%

Net Profit Margin (Annual)-56.05%

Month-to-Date Return-17.65%

EBITD / Share (Annual)$0.34

Operating Margin (Annual)-38.83%

P/CF (TTM)6.57x

ROI (5Y Avg)-37.79%

P/E Excl Extra (TTM)5.28x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$0.36

P/TBV (Quarterly)1.06x

P/B Ratio (Annual)1.39x

Inventory Turnover (TTM)24.20x

Pretax Margin (TTM)-420.49%

Book Value / Share (Annual)$1.09

Price vs S&P 500 (13W)-19.98%

Beta2.79x

P/FCF (Annual)5.93x

Revenue / Share (TTM)$0.09

ROE (TTM)42.57%

52-Week Low$1.43

vGradeB

gGradeA

mGradeC

vgmGradeB

CGEN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	-$0.09	-$0.07	+17.65%(+$0.02)
Q1 2026	May 18, 2026	-$0.08	-$0.08	+0.00%(+$0.00)
Q4 2025	Mar 2, 2026	$0.14	$0.60	+339.01%(+$0.46)
Q3 2025	Nov 10, 2025	-$0.09	-$0.07	+22.22%(+$0.02)
Q2 2025	Aug 6, 2025	-$0.09	-$0.08	+5.88%(+$0.01)

CGEN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.36

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CGENCompugen Ltd	B	A	C	7.5x	161.1%	87.0%	—	$1.96
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Compugen Ltd

Compugen Ltd is a clinical-stage biopharmaceutical company developing cancer immunotherapies using computational drug discovery to identify novel immune targets. The company has four programs in clinical development targeting immune checkpoints and resistance pathways, including COM701, COM902, and bapotulimab, plus early-stage programs focusing on myeloid targets.